Sesen Bio, Inc. (SESN)
After hours:
| Previous close | 0.3910 |
| Open | 0.3900 |
| Bid | 0.3800 x 1200 |
| Ask | 0.3988 x 1200 |
| Day's range | 0.3800 - 0.3970 |
| 52-week range | 0.3650 - 1.4700 |
| Volume | |
| Avg. volume | 1,992,631 |
| Market cap | 77.651M |
| Beta (5Y monthly) | 0.65 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Sesen Bio and Carisma Therapeutics Announce Merger Agreement
CAMBRIDGE, Mass. & PHILADELPHIA, September 21, 2022--Sesen Bio, Inc. (Nasdaq: SESN) and Carisma Therapeutics Inc. (Carisma), a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Carisma’s proprietary cell therapy platform that utilizes engineered
- Business Wire
Sesen Bio Reports Second Quarter 2022 Financial Results and Business Update
CAMBRIDGE, Mass., August 08, 2022--Sesen Bio (Nasdaq: SESN) today reported operating results for the second quarter ended June 30, 2022. During the quarter, the Company paused clinical development of its lead asset, Vicineum™ for the treatment of non-muscle invasive bladder cancer (NMIBC), and turned its primary focus to the assessment of potential strategic alternatives with the goal of maximizing shareholder value, which it believes will be complete by the end of 2022.
- Business Wire
Sesen Bio Announces Strategic Decision to Pause Clinical Development of Vicineum™ in the US
CAMBRIDGE, Mass., July 18, 2022--Sesen Bio (Nasdaq: SESN) today announced that it has made the strategic decision to voluntarily pause further development in the US of its lead asset, Vicineum. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial for the treatment of non-muscle invasive bladder cancer (NMIBC), following recent discussions with the US Food & Drug Administrat
